Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
All of these results demonstrated that FSTL3 as a novelty cytokine takes part in the process of atherosclerosis through increasing lipid accumulation and inflammation through regulating CD36 and LOX-1 expression.
|
31815869 |
2019 |
Asthma
|
0.010 |
Biomarker
|
disease |
BEFREE |
To quantify the abundance of the total proteome FSTL3 and activin A in supernatants of differentiated BEC cultures from healthy children and children with asthma, we performed mass spectrometry and ELISA.
|
29394092 |
2018 |
Atherosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
All of these results demonstrated that FSTL3 as a novelty cytokine takes part in the process of atherosclerosis through increasing lipid accumulation and inflammation through regulating CD36 and LOX-1 expression.
|
31815869 |
2019 |
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Here we evaluate FSTL3 as a prognostic tool and its relation with clinical and pathological features of breast cancer.
|
28178680 |
2017 |
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
We showed that members of the IGF-1/IGFBP-4/PAPP-A axis and FSTL-3 may serve as surrogate markers in breast cancer.
|
30388235 |
2019 |
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Finally, a strong expression of FLRG was observed in invasive breast carcinomas in contrast with the normal luminal epithelial cells in which FLRG was not detected.
|
17671190 |
2007 |
Cardiac fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
We found that FSTL3 is necessary for this response and for the induction of cardiac fibrosis.
|
22915069 |
2012 |
Cardiovascular Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
We assessed the predictive value of GAL3 (galectin-3), FSTL3 (follistatin-like 3 peptide), and NT-proBNP (N-terminal pro-B-type natriuretic peptide) to identify stage B MHD in young obese participants free of clinically evident cardiovascular disease.
|
30929550 |
2019 |
Cerebrovascular accident
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Framingham 10-year stroke risk (FSRP-10) quantified CVD-RFs.
|
30980900 |
2019 |
Chronic Kidney Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Moreover, mFSTL3 mRNA expression was investigated in an animal CKD model, that is, eNOS-/-db/db mice, and compared with littermate controls.
|
28339962 |
2017 |
Congestive heart failure
|
0.030 |
Biomarker
|
disease |
BEFREE |
In humans, we found that circulating FSTL3 increased with aging, frailty, and HF severity, correlating with an increase in circulating activins.
|
30842316 |
2019 |
Congestive heart failure
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Real-time PCR revealed that FSTL1 and FSTL3 expression was elevated in heart failure but returned to normal after recovery.
|
18617621 |
2008 |
Congestive heart failure
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
FSTL3 expression is elevated in patients with heart failure and is upregulated in cardiomyocytes by hypertrophic stimuli, but its role in cardiac remodelling is largely unknown.
|
22915069 |
2012 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We investigated this hypothesis in humans by studying the physiology of a possible glycaemia-follistatin feedback loop, that is, whether glucose, but not lipid intake (oral or intravenous), can regulate circulating FST and FSTL3 in healthy humans (n = 32), whether the levels of follistatins change in response to various types of bariatric operation in morbidly obese individuals, with or without type 2 diabetes (n = 41), and whether such changes are associated prospectively with improvement of glucose homeostasis/insulin sensitivity.
|
30393997 |
2019 |
Diminished ovarian reserve
|
0.010 |
Biomarker
|
disease |
BEFREE |
Forty-eight transcripts were differentially expressed, including CXXC finger protein 5 (CXXC5), forkhead box C1 (FOXC1) (down-regulated in DOR) as well as connective tissue growth factor (CTGF), follistatin-like 3 (FSTL3), prostaglandin-endoperoxide synthase 2 (PTGS2) and suppressor of cytokine signaling 2 (SOCS2) (up-regulated in DOR).
|
22246450 |
2012 |
Dyslipidemias
|
0.010 |
Biomarker
|
group |
BEFREE |
FSTL3 as adipokine takes part in dyslipidemia and inflammatory response, but the association of FSTL3 with atherosclerosis is unclear.
|
31815869 |
2019 |
Eclampsia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Overproduction of the follistatin-related gene protein in the placenta and maternal serum of women with pre-eclampsia.
|
17617189 |
2007 |
Fatty Liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
Both FSTL3-knockout and FST288-only mice had extensive hepatic steatosis and elevated hepatic triglyceride content.
|
23533219 |
2013 |
Fetal Growth Retardation
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Our results suggest that IGFBP1 and Follistatin-like 3 are highly up-regulated in IUGR in the placenta.
|
16338475 |
2006 |
Fetal Growth Retardation
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Microarray experiments identified increased expression of certain genes including leptin, soluble vascular endothelial growth factor receptor, human chorionic gonadotropin, follistatin-like 3, and hypoxia-inducible factor 2alpha in the IUGR.
|
17240240 |
2007 |
Gestational Diabetes
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
There were no significant differences in serum FSTL3 levels (p = 0.578) between the GDM group and the GDM-free control group.
|
27623975 |
2017 |
Heart failure
|
0.030 |
Biomarker
|
disease |
BEFREE |
In humans, we found that circulating FSTL3 increased with aging, frailty, and HF severity, correlating with an increase in circulating activins.
|
30842316 |
2019 |
Heart failure
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Real-time PCR revealed that FSTL1 and FSTL3 expression was elevated in heart failure but returned to normal after recovery.
|
18617621 |
2008 |
Heart failure
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
FSTL3 expression is elevated in patients with heart failure and is upregulated in cardiomyocytes by hypertrophic stimuli, but its role in cardiac remodelling is largely unknown.
|
22915069 |
2012 |
Invasive carcinoma of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
FSTL3 expression in invasive breast cancer is inversely associated with tumor size and nuclear grade but it does not predict disease relapse in the short term.
|
28178680 |
2017 |